Review
Oncology
Xinrun Cui, Xiang Li, Chao Lv, Shi Yan, Jia Wang, Nan Wu
Summary: Adjuvant therapy with EGFR tyrosine kinase inhibitor (TKI), alone or with chemotherapy, is effective for early-stage non-small cell lung cancer (NSCLC) with EGFR mutations. A Bayesian meta-analysis compared the efficacy and safety of adjuvant EGFR-TKI and adjuvant chemotherapy plus EGFR-TKI. The analysis showed that EGFR-TKI monotherapy is noninferior to chemotherapy plus EGFR-TKI in terms of disease-free survival (DFS) and overall survival (OS) in the adjuvant setting. However, combination treatment had a higher incidence and severity of adverse events (AEs). Adjuvant EGFR-TKI monotherapy is a viable alternative to chemotherapy plus EGFR-TKI for resected EGFR mutation-positive NSCLC patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Yasuhiro Tsutani, Jonathan W. Goldman, Sanja Dacic, Yasushi Yatabe, Margarita Majem, Xiangning Huang, Allen Chen, Toon van der Gronde, Jie He
Summary: ADAURA2 is a clinical study designed to evaluate the efficacy of adjuvant osimertinib compared to placebo in patients with completely resected EGFR mutation-positive non-small cell lung cancer. The study aims to assess disease-free survival in high-risk patients, with secondary endpoints including overall survival and CNS disease-free survival.
CLINICAL LUNG CANCER
(2023)
Article
Oncology
Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada, Ichiro Yoshino, Jiro Okami, Kazuhisa Takahashi, Norihiko Ikeda, Masayuki Tanahashi, Yuichi Tambo, Haruhiro Saito, Shinichi Toyooka, Hidetoshi Inokawa, Toyofumi Chen-Yoshikawa, Toshihide Yokoyama, Tatsuro Okamoto, Noriko Yanagitani, Masahide Oki, Makoto Takahama, Kenji Sawa, Hirohito Tada, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Kazuto Nishio
Summary: The NOTCH1 and CREBBP mutations might predict poor outcome in patients treated with gefitinib and cis/vin, respectively, for completely resected EGFR-mutated NSCLC.
MOLECULAR ONCOLOGY
(2023)
Review
Oncology
Walid Shalata, Binil Mathew Jacob, Abed Agbarya
Summary: This review article provides an overview of the advancements in non-small cell lung cancer treatments, focusing on the special mutation of EGFR. The article discusses past chemotherapy trials, current tyrosine kinase inhibitor (TKI) trials, and ongoing trials that combine both approaches. Future research should emphasize metastasis to the brain and central nervous system in lung cancer treatment.
Article
Oncology
Mark G. Kris, Tetsuya Mitsudomi, Solange Peters
Summary: Surgical resection followed by adjuvant cisplatin-based chemotherapy is recommended for stage IB-IIIA NSCLC. Recurrence rates are high, and EGFR-TKIs have improved outcomes for metastatic and EGFR-mutated lung cancers. Early identification of EGFR mutations is crucial for personalized treatment.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Article
Oncology
Swati Soni, Ashu Rastogi, Kuruswamy T. Prasad, Digambar Behera, Navneet Singh
Summary: This study aimed to evaluate the incidence of thyroid dysfunction in NSCLC patients treated with EGFR and ALK inhibitors, showing that 8% of patients developed thyroid dysfunction typically within one month of treatment initiation. However, all patients were asymptomatic and none required interruption or cessation of TKI treatment.
Article
Oncology
Zichun Li, Xuanye Zhang, Yuhong Wang, Zhixin Yu, Chunlong Yang, Yixin Zhou, Shaodong Hong
Summary: A comparative analysis suggests that osimertinib is a more suitable adjuvant therapy than immunotherapy for completely resected EGFR-mutant NSCLC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko
Summary: This meta-analysis revealed significant differences in resistance mechanisms among different epidermal growth factor receptor tyrosine kinase inhibitors, such as T790M mutation. These differences should be considered when choosing treatment strategies.
Review
Medicine, General & Internal
Ran Cui, Chun Wei, Xianyi Li, Ou Jiang
Summary: Adjuvant EGFR-TKI combined with chemotherapy achieved superior effect over chemotherapy or placebo in terms of disease-free survival (DFS) for non-small cell lung cancer (NSCLC) cases harboring EGFR mutations, and may prolong overall survival (OS) to some extent.
Article
Oncology
Rahul Shenolikar, Sizhu Liu, Anne Shah, Jenny Tse, Yao Cao, Aimee Near
Summary: This study analyzed real-world data to examine first-line treatments with EGFR TKIs in the United States, finding that osimertinib had longer treatment duration compared with other EGFR TKIs.
Review
Oncology
Marisa L. Martin-Fernandez
Summary: Lung cancer is a major cause of cancer-related deaths with a low survival rate. Small-molecule drugs that block cancer-driven molecular activity have shown initial success, but resistance develops within approximately one year of therapy.
Article
Oncology
Robin Guo, Michael Offin, A. Rose Brannon, Jason Chang, Andrew Chow, Lukas Delasos, Jeffrey Girshman, Olivia Wilkins, Caroline G. McCarthy, Alex Makhnin, Christina Falcon, Kerry Scott, Yuan Tian, Fabiola Cecchi, Todd Hembrough, Deepu Alex, Ronglai Shen, Ryma Benayed, Bob T. Li, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Natasha Rekhtman, Paul Paik, Ahmet Zehir, Alexander Drilon
Summary: In MET exon 14-altered lung cancers treated with a MET TKI, the genomic mechanisms of primary resistance remain unknown, while MET expression is correlated with treatment benefit.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Jaewon Hyung, Hyunseok Yoon, Chang-Min Choi, Shinkyo Yoon, Dae Ho Lee, Sang-we Kim, Hyeong-ryul Kim, Su Ssan Kim, Si Yeol Song, Jae Cheol Lee
Summary: This study found that the efficacy of EGFR TKIs in EGFR-mutated NSCLC patients who recurred after RT was comparable to that in RT-naive advanced NSCLC patients treated with EGFR TKIs, suggesting that RT may not affect the efficacy of EGFR TKIs.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Chao Wang, Yujing Zhang, Tingting Zhang, Jiazhen Xu, Saisai Yan, Bing Liang, Dongming Xing
Summary: Overexpression of EGFR has been linked to various cancers, and drug resistance caused by EGFR mutations is a significant challenge. EGFR dual-target inhibitors show promise in overcoming drug resistance and have higher efficacy compared to single-target inhibitors.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
